ArticleOncology letters2020
lncRNA-CD160 decreases the immunity of CD8
Article in Oncology letters, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 25 citations in OpenAlex.
- Current progress and role of lncRNAs in HBV infection and progression of hepatocellular carcinoma.Genes & diseases · 2026Review
- A Systematic Review of the Advances in the Study of T Lymphocyte Suppressor Receptors in HBV Infection: Potential Therapeutic Targets.Journal of clinical medicine · 2024Review
- Research progress on the mechanism of exosome-mediated virus infection.Frontiers in cellular and infection microbiology · 2024Review
- Identification and function of a novel human memory-like NK cell population expressing CD160 in melioidosis.iScience · 2023Article
- Long noncoding RNAs in hepatitis B virus replication and oncogenesis.World journal of gastroenterology · 2022Review
- When does hepatitis B virus meet long-stranded noncoding RNAs?Frontiers in microbiology · 2022Review
- HDAC11, an emerging therapeutic target for metabolic disorders.Frontiers in endocrinology · 2022Review
- Emerging Role of Non-Coding RNAs in Regulation of T-Lymphocyte Function.Frontiers in immunology · 2021Review
- Exosomal lncRNA HOTTIP Mediates Antiviral Effect of Tenofovir Alafenamide (TAF) on HBV Infection.Journal of inflammation research · 2021Article
- Potential impact and mechanism of Long Non-coding RNAs on cancer and associated T cells.Journal of Cancer · 2021Review
- Long noncoding RNA: a dazzling dancer in tumor immune microenvironment.Journal of experimental & clinical cancer research : CR · 2020Review
Corrections and comments
- Retraction · 2025-05-06Author Unresponsive · Concerns/Issues about Data · Euphemisms for Plagiarism · Investigation by Journal/Publisher · Investigation by Third Party · Plagiarism of Data · · See also: https://pubpeer.com/publications/6A79BAABFDFB324B0A07863A0A5630
- Retracted
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The transfer and development of chronic hepatitis B virus (HBV) infection is associated with the T cell immune response, therefore investigating the key regulators of cell immune response is needed to improve chronic HBV treatment. Blood samples from patients with chronic HBV infection were used to confirm the correlation between HBV infection stage and CD160 receptor expression levels in CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.